EGFR and non-small cell lung carcinoma: A total of 102 patients with NSCLC harboring activating EGFR mutations were enrolled in this prospective trial of first-generation EGFR-TKI between September 2011 and March 2015 at Yonsei Cancer Center in Korea (Figure 1).